Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):799–809. doi: 10.1161/ATVBAHA.118.312328

Figure 1: Binding properties of AB023.

Figure 1:

(A) Western blots of non-reducing 10% polyacrylamide gel of human FXI (lane 1) and human FXI in which the A1, A2, A3, or A4 domain has been replaced with the corresponding domain from prekallikrein (PK). (B) Western blots of non-reducing 10% polyacrylamide gel of individual human FXI apple domains (A1-A4) linked to recombinant tPA. AB023 recognizes the A2 domain of human FXI. (C) Binding of AB023 to human FXI (closed circles), human FXIa (open square). (D) AB023 concentration-dependently inhibits FXIIa activation of FXI. (E) AB023 does not prevent activation of FXI by thrombin. (F) AB023 prolongs the aPTT in a concentration dependent manner in plasma from human (black circles), baboons (open squares), cynomolgus monkeys (open circles) and rats (open diamonds). *The FXI/PKA4 chimeric protein (A4*) is a dimeric molecule created by replacing Cys326 with alanine in PK A4 domain.